Previous disorders and depression outcomes in individuals with 12-month major depressive disorder in the World Mental Health surveys

Annelieke M. Roest; Ymkje Anna de Vries; Ali Al-Hamzawi; Jordi Alonso; Olatunde O. Ayinde; Ronny Bruffaerts; Brendan Bunting; Jose Miguel Caldas de Almeida; Giovanni de Girolamo; Louisa Degenhardt; Silvia Florescu; Oye Gureje; Josep Maria Haro; Chiyi Hu; Elie G. Karam; Andrzej Kiejna; Viviane Kovess-Masfety; Sing Lee; John J. McGrath; Maria Elena Medina-Mora; Fernando Navarro-Mateu; Daisuke Nishi; Marina Piazza; Jose Posada-Villa; Kate M. Scott; Juan Carlos Stagnaro; Dan J. Stein; Yolanda Torres; Maria Carmen Viana; Zahari Zarkov; Ronald C. Kessler; Peter de Jonge; WHO World Mental Hlth Survey Colla

doi:10.1017/S2045796021000573

Back

Previous disorders and depression outcomes in individuals with 12-month major depressive disorder in the World Mental Health surveys

Journal article

Open access

Peer reviewed

Previous disorders and depression outcomes in individuals with 12-month major depressive disorder in the World Mental Health surveys

Annelieke M. Roest, Ymkje Anna de Vries, Ali Al-Hamzawi, Jordi Alonso, Olatunde O. Ayinde, Ronny Bruffaerts, Brendan Bunting, Jose Miguel Caldas de Almeida, Giovanni de Girolamo, Louisa Degenhardt, …

Epidemiology and psychiatric sciences, Vol.30, pp.3-9

11/11/2021

DOI: https://doi.org/10.1017/S2045796021000573

Handle:

https://hdl.handle.net/10523/19474

Abstract

Life Sciences & Biomedicine

Psychiatry

Science & Technology

Aims Major depressive disorder (MDD) is characterised by a recurrent course and high comorbidity rates. A lifespan perspective may therefore provide important information regarding health outcomes. The aim of the present study is to examine mental disorders that preceded 12-month MDD diagnosis and the impact of these disorders on depression outcomes. Methods Data came from 29 cross-sectional community epidemiological surveys of adults in 27 countries (n = 80 190). The Composite International Diagnostic Interview (CIDI) was used to assess 12-month MDD and lifetime DSM-IV disorders with onset prior to the respondent's age at interview. Disorders were grouped into depressive distress disorders, non-depressive distress disorders, fear disorders and externalising disorders. Depression outcomes included 12-month suicidality, days out of role and impairment in role functioning. Results Among respondents with 12-month MDD, 94.9% (s.e. = 0.4) had at least one prior disorder (including previous MDD), and 64.6% (s.e. = 0.9) had at least one prior, non-MDD disorder. Previous non-depressive distress, fear and externalising disorders, but not depressive distress disorders, predicted higher impairment (OR = 1.4-1.6) and suicidality (OR = 1.5-2.5), after adjustment for sociodemographic variables. Further adjustment for MDD characteristics weakened, but did not eliminate, these associations. Associations were largely driven by current comorbidities, but both remitted and current externalising disorders predicted suicidality among respondents with 12-month MDD. Conclusions These results illustrate the importance of careful psychiatric history taking regarding current anxiety disorders and lifetime externalising disorders in individuals with MDD.

Files and links (1)

url

https://doi.org/10.1017/S2045796021000573View

Published (Version of record) Open

Metrics

6 Record Views

7 Times Cited - Web of Science

See more details

Details

Record Identifier: 9926495509601891
Title: Previous disorders and depression outcomes in individuals with 12-month major depressive disorder in the World Mental Health surveys
Creators: Annelieke M. Roest
Ymkje Anna de Vries
Ali Al-Hamzawi
Jordi Alonso
Olatunde O. Ayinde
Ronny Bruffaerts
Brendan Bunting
Jose Miguel Caldas de Almeida
Giovanni de Girolamo
Louisa Degenhardt
Silvia Florescu
Oye Gureje
Josep Maria Haro
Chiyi Hu
Elie G. Karam
Andrzej Kiejna
Viviane Kovess-Masfety
Sing Lee
John J. McGrath
Maria Elena Medina-Mora
Fernando Navarro-Mateu
Daisuke Nishi
Marina Piazza
Jose Posada-Villa
Kate M. Scott
Juan Carlos Stagnaro
Dan J. Stein
Yolanda Torres
Maria Carmen Viana
Zahari Zarkov
Ronald C. Kessler
Peter de Jonge
WHO World Mental Hlth Survey Colla
Publication Details: Epidemiology and psychiatric sciences, Vol.30, pp.3-9
Academic Unit: Psychological Medicine (DSM)
Publisher: Cambridge Univ Press
Grant note: National Center for Public Health Protection WHO (Geneva); World Health Organization Ministry of Social Protection Algorithm National Institute of Health of the Ministry of Health of Peru Substance Abuse and Mental Health Services Administration (SAMHSA); United States Department of Health & Human Services Eli Lilly and Company; Eli Lilly R03 TW006481-01 / National Institute of Health/Fogarty International Center; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC) WHO (Nigeria); World Health Organization H13-SHOGAI-023; H14-TOKUBETSU-026; H16-KOKORO-013; H25-SEISHIN-IPPAN-006 / Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour and Welfare Health Research Council; Health Research Council of New Zealand Lundbeck; Lundbeck Corporation Shenzhen Bureau of Health Fundacion para la Formacion e Investigacion Sanitarias (FFIS) of Murcia Glaxo Smith Kline; GlaxoSmithKline Iraqi IMHS team OmniPharma Health & Social Care Research & Development Division of the Public Health Agency 044708 / Robert Wood Johnson Foundation (RWJF) 03/00204-3 / State of Sao Paulo Research Foundation (FAPESP) Thematic Project Grant; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) FIS 00/0028 / Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain; Instituto de Salud Carlos III Eli Lilly Servier Ministry of Health Pfizer Pan American Health Organization WHO (Lebanon); World Health Organization South African Department of Health University of Michigan; University of Michigan System R01 MH070884 / United States National Institute of Mental Health (NIMH); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH) Center for Excellence on Research in Mental Health (CES University) Norwegian Financial Mechanism SAF 2000-158-CE / Ministerio de Ciencia y Tecnologia, Spain; Spanish Government Bella Pharma Champalimaud Foundation Ortho-McNeil Pharmaceutical Inc. John W. Alden Trust 2017 SGR 452; 2014 SGR 748 / Generalitat de Catalunya Japanese Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF) Lebanese Ministry of Public Health Bristol-Myers Squibb Australian Government Department of Health and Ageing; Australian Government; Department of Health & Ageing Piedmont Region (Italy); Regione Piemonte; Instituto de Salud Carlos III Gulbenkian Foundation Ministry of Public Health European Economic Area Financial Mechanism CIBER CB06/02/0046; RETICS RD06/0011 REM-TAP / Instituto de Salud Carlos III; Spanish Government Medical Research Council of South Africa (MRC) UPO Polish Ministry of Health R01-MH059575; RO1-MH61905 / US National Institute of Mental Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH) Pfizer Foundation 2002-17270/13-5 / Argentinian Ministry of Health (Ministerio de Salud de la Nacion) National Institute of Drug Abuse (NIDA); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA) National Institute of Drug Abuse; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA) Israel National Institute for Health Policy and Health Services Research European Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF) Phenicia John D. and Catherine T. MacArthur Foundation R13-MH066849; R01-MH069864; R01 DA016558 / United States Public Health Service; United States Department of Health & Human Services Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejeria de Sanidad y Politica Social) AstraZeneca New Zealand Ministry of Health, Alcohol Advisory Council Foundation for Science and Technology (FCT); Fundacao para a Ciencia e a Tecnologia (FCT) 4280 / National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES) Benta Eli Lilly Romania SRL; Eli Lilly Shenzhen Bureau of Science, Technology, and Information Novartis U01-MH60220 / National Institute of Mental Health (NIMH); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH) Secretary of Health of Medellin FIRCA R03-TW006481 / Fogarty International Center; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC) GlaxoSmithKline PL 0256 / project Epidemiology of Mental Health National Insurance Institute of Israel G30544-H / National Council on Science and Technology (CONACyT); Consejo Nacional de Ciencia y Tecnologia (CONACyT) Federal Ministry of Health, Abuja, Nigeria QLG5-1999-01042; SANCO 2004123; EAHC 20081308 / European Commission; European Union (EU); European Commission Joint Research Centre
Date published ; e-published: 11/11/2021
Language: English
Resource Type ; Subtype: Journal article